The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 1 study of repeat radiation, minocycline, and bevacizumab in patients with recurrent glioma (RAMBO).
Adam Louis Cohen
No relevant relationships to disclose
Christopher James Anker
No relevant relationships to disclose
Karen Salzman
No relevant relationships to disclose
Randy L. Jensen
No relevant relationships to disclose
Dennis C. Shrieve
No relevant relationships to disclose
Howard Colman
Consultant or Advisory Role - Genentech; Roche; Sigma-Tau
Stock Ownership - Castle Biosciences
Honoraria - Merck